Lv54
1406 积分 2021-07-16 加入
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
3小时前
已完结
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
3小时前
已完结
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion
3小时前
已完结
Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy
4小时前
已完结
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
8小时前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
8小时前
已完结
Accelerating progress in immune cell therapy for solid tumours
10小时前
求助中
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
10小时前
已完结
Retargeted retrotransposons insert multi-kilobase cargo at new sites
11小时前
已完结
Fine tuning towards the next generation of engineered T cells
11小时前
已完结
皖公网安备34019202002308
